Over 1 Year Ago
1 Min Read
Shares of GRTS are trading -13% lower today. A closer look at what's happening:
Shares of Gritstone Oncology Inc (GRTS) are trading -13% lower at a price of $3.63 at the time of this writing. While it's a mildly dispirited day for the Health Care sector in general, the stock is lagging behind it's peers.
The stock was recently downgraded to a sell rating by Goldman Sachs, which may be moving the price today. Although in the last few days some firms have been increasing their positions in the company:
- Belvedere Trading LLC increased its stake in Gritstone bio by 14.7% in the first quarter, owning 25,134 shares valued at $85,000 after purchasing 3,223 additional shares during the period.
- Itau Unibanco Holding S.A. purchased a new position in Gritstone bio shares in the fourth quarter, valued at $53,000.
- Advisor Group Holdings Inc. increased their stake in Gritstone bio shares by 880% in the fourth quarter.
- Daiwa Securities Group Inc. purchased a new position in Gritstone bio shares in the fourth quarter, valued at $98,000.
Gritstone Oncology Inc has been trading between a 52-week high of $14.42 and a 52-week low of $1.71. The stock has a market cap of $264 Million.
Gritstone bio, Inc., a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone develops its products by leveraging two key pillars—first, a proprietary machine learning-based platform, Gritstone EDGETM, which is designed to predict antigens that are presented on the surface of cells, such as tumor or virally-infected cells, that can be seen by the immune system; and, second, the ability to develop and manufacture potent immunotherapies utilizing these antigens to potentially drive the patient’s immune system to specifically attack and destroy disease-causing cells. The company’s lead oncology programs include an individualized neoantigen-based immunotherapy, GRANITE, and an “off-the-shelf” shared neoantigen-based immunotherapy, SLATE, which are being evaluated in clinical studies.
The stock was recently downgraded to a sell rating by Goldman Sachs, which may be moving the price today. Although in the last few days some firms have been increasing their positions in the company:
- Belvedere Trading LLC increased its stake in Gritstone bio by 14.7% in the first quarter, owning 25,134 shares valued at $85,000 after purchasing 3,223 additional shares during the period.
- Itau Unibanco Holding S.A. purchased a new position in Gritstone bio shares in the fourth quarter, valued at $53,000.
- Advisor Group Holdings Inc. increased their stake in Gritstone bio shares by 880% in the fourth quarter.
- Daiwa Securities Group Inc. purchased a new position in Gritstone bio shares in the fourth quarter, valued at $98,000.
Gritstone Oncology Inc has been trading between a 52-week high of $14.42 and a 52-week low of $1.71. The stock has a market cap of $264 Million.
Gritstone bio, Inc., a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone develops its products by leveraging two key pillars—first, a proprietary machine learning-based platform, Gritstone EDGETM, which is designed to predict antigens that are presented on the surface of cells, such as tumor or virally-infected cells, that can be seen by the immune system; and, second, the ability to develop and manufacture potent immunotherapies utilizing these antigens to potentially drive the patient’s immune system to specifically attack and destroy disease-causing cells. The company’s lead oncology programs include an individualized neoantigen-based immunotherapy, GRANITE, and an “off-the-shelf” shared neoantigen-based immunotherapy, SLATE, which are being evaluated in clinical studies.
Recommended Articles
